Bio Preventive Medicine today announce its participation in the upcoming 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit, which will gather stakeholders and decision-makers from the USFDA, academia, and influential international pharma across the globe.
Dr. Tzu-Ling (Karen) Tseng, CEO of BPM, is arranged to deliver a talk, From Diagnostic to Therapeutic Targets, on March 3rd from 12:00-12:30 (Eastern Standard Time, USA).
As a solution provider, BPM can assist our pharma partners in drug development, not only for evaluating renal efficacy, but also renal safety. We believe this is an excellent exposure for BPM to become a global player in CKD drug development area.
For more information, please visit CKD3 official website:
https://ckd3-summit.com/
BPM Virtual Booth:
https://ckd3-summit.com/bio-preventive-medicine-virtual-booth/
Dr. Tzu-Ling (Karen) Tseng, CEO of BPM, is arranged to deliver a talk, From Diagnostic to Therapeutic Targets, on March 3rd from 12:00-12:30 (Eastern Standard Time, USA).
As a solution provider, BPM can assist our pharma partners in drug development, not only for evaluating renal efficacy, but also renal safety. We believe this is an excellent exposure for BPM to become a global player in CKD drug development area.
For more information, please visit CKD3 official website:
https://ckd3-summit.com/
BPM Virtual Booth:
https://ckd3-summit.com/bio-preventive-medicine-virtual-booth/